Cardiac protection with phosphocreatine: A meta-analysis

Giovanni Landoni, Alberto Zangrillo, Vladimir V. Lomivorotov, Valery Likhvantsev, Jun Ma, Francesco De Simone, Evgeny Fominskiy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Phosphocreatine (PCr) plays an important role in the energy metabolism of the heart and a decrease in its intracellular concentration results in alteration of myocardium energetics and work. We conducted a meta-analysis of all randomized and matched trials that compared PCr with placebo or standard treatment in patients with coronary artery disease or chronic heart failure or in those undergoing cardiac surgery. We systematically searched PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials and Google Scholar up to 1 November 2015, for pertinent trials. The primary outcome was all-cause mortality. Secondary outcomes included inotrope use, ejection fraction (EF), peak creatinine kinase-myocardial band (CK-MB) release and the incidence of major arrhythmias, as well as spontaneous recovery of the heart performance in the subgroup of patients undergoing cardiac surgery with cardiopulmonary bypass. We pooled odds ratio (OR) and mean difference (MD) using fixed- and random effects models. We identified 41 controlled trials, of them 32 were randomized. Patients receiving PCr had lower all-cause mortality when compared with the control group [61/1731 (3.5%) vs 177/1667 (10.6%); OR: 0.71, 95% CI: 0.51-0.99; P = 0.04; I2 = 0%; with 3400 patients and 22 trials included]. Phosphocreatine administration was associated with higher LVEF (MD: 3.82, 95% CI: 1.18-6.46; P = 0.005; I2 = 98%), lower peak CK-MB release (MD: -6.08, 95% CI: -8.01, -4.15; P < 0.001; I2 = 97%), lower rate of major arrhythmias (OR: 0.42; 95% CI: 0.27-0.66; P < 0.001; I2 = 0%), lower incidence of inotropic support (OR: 0.39, 95% CI: 0.25-0.61; P < 0.001; I2 = 56%) and a higher level of spontaneous recovery of the heart performance after cardiopulmonary bypass (OR: 3.49, 95% CI: 2.28-5.35; P < 0.001; I2 = 49%) when compared with the control group. In a mixed population of patients with coronary artery disease, chronic heart failure or in those undergoing cardiac surgery, PCr may reduce all-cause short-term mortality. In addition, PCr administration was associated with improved cardiac outcomes. Owing to the pharmacological plausibility of this effect and to the concordance of the beneficial effects of PCr on several secondary but important outcomes and survival, there is urgent need for a large multicentre randomized trial to confirm these findings.

Original languageEnglish
Pages (from-to)637-646
Number of pages10
JournalInteractive Cardiovascular and Thoracic Surgery
Volume23
Issue number4
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Phosphocreatine
Meta-Analysis
Odds Ratio
Thoracic Surgery
Cardiopulmonary Bypass
Mortality
Cardiac Arrhythmias
Coronary Artery Disease
Creatinine
Phosphotransferases
Heart Failure
Control Groups
Incidence
PubMed
Energy Metabolism
Multicenter Studies
Myocardium
Placebos
Pharmacology
Survival

Keywords

  • Cardiac surgery
  • Heart failure
  • Mortality
  • Myocardial infarction
  • Phosphocreatine

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Cardiac protection with phosphocreatine : A meta-analysis. / Landoni, Giovanni; Zangrillo, Alberto; Lomivorotov, Vladimir V.; Likhvantsev, Valery; Ma, Jun; De Simone, Francesco; Fominskiy, Evgeny.

In: Interactive Cardiovascular and Thoracic Surgery, Vol. 23, No. 4, 01.10.2016, p. 637-646.

Research output: Contribution to journalArticle

Landoni, G, Zangrillo, A, Lomivorotov, VV, Likhvantsev, V, Ma, J, De Simone, F & Fominskiy, E 2016, 'Cardiac protection with phosphocreatine: A meta-analysis', Interactive Cardiovascular and Thoracic Surgery, vol. 23, no. 4, pp. 637-646. https://doi.org/10.1093/icvts/ivw171
Landoni, Giovanni ; Zangrillo, Alberto ; Lomivorotov, Vladimir V. ; Likhvantsev, Valery ; Ma, Jun ; De Simone, Francesco ; Fominskiy, Evgeny. / Cardiac protection with phosphocreatine : A meta-analysis. In: Interactive Cardiovascular and Thoracic Surgery. 2016 ; Vol. 23, No. 4. pp. 637-646.
@article{a1620a3a89ab4b63951a93047a065e2d,
title = "Cardiac protection with phosphocreatine: A meta-analysis",
abstract = "Phosphocreatine (PCr) plays an important role in the energy metabolism of the heart and a decrease in its intracellular concentration results in alteration of myocardium energetics and work. We conducted a meta-analysis of all randomized and matched trials that compared PCr with placebo or standard treatment in patients with coronary artery disease or chronic heart failure or in those undergoing cardiac surgery. We systematically searched PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials and Google Scholar up to 1 November 2015, for pertinent trials. The primary outcome was all-cause mortality. Secondary outcomes included inotrope use, ejection fraction (EF), peak creatinine kinase-myocardial band (CK-MB) release and the incidence of major arrhythmias, as well as spontaneous recovery of the heart performance in the subgroup of patients undergoing cardiac surgery with cardiopulmonary bypass. We pooled odds ratio (OR) and mean difference (MD) using fixed- and random effects models. We identified 41 controlled trials, of them 32 were randomized. Patients receiving PCr had lower all-cause mortality when compared with the control group [61/1731 (3.5{\%}) vs 177/1667 (10.6{\%}); OR: 0.71, 95{\%} CI: 0.51-0.99; P = 0.04; I2 = 0{\%}; with 3400 patients and 22 trials included]. Phosphocreatine administration was associated with higher LVEF (MD: 3.82, 95{\%} CI: 1.18-6.46; P = 0.005; I2 = 98{\%}), lower peak CK-MB release (MD: -6.08, 95{\%} CI: -8.01, -4.15; P < 0.001; I2 = 97{\%}), lower rate of major arrhythmias (OR: 0.42; 95{\%} CI: 0.27-0.66; P < 0.001; I2 = 0{\%}), lower incidence of inotropic support (OR: 0.39, 95{\%} CI: 0.25-0.61; P < 0.001; I2 = 56{\%}) and a higher level of spontaneous recovery of the heart performance after cardiopulmonary bypass (OR: 3.49, 95{\%} CI: 2.28-5.35; P < 0.001; I2 = 49{\%}) when compared with the control group. In a mixed population of patients with coronary artery disease, chronic heart failure or in those undergoing cardiac surgery, PCr may reduce all-cause short-term mortality. In addition, PCr administration was associated with improved cardiac outcomes. Owing to the pharmacological plausibility of this effect and to the concordance of the beneficial effects of PCr on several secondary but important outcomes and survival, there is urgent need for a large multicentre randomized trial to confirm these findings.",
keywords = "Cardiac surgery, Heart failure, Mortality, Myocardial infarction, Phosphocreatine",
author = "Giovanni Landoni and Alberto Zangrillo and Lomivorotov, {Vladimir V.} and Valery Likhvantsev and Jun Ma and {De Simone}, Francesco and Evgeny Fominskiy",
year = "2016",
month = "10",
day = "1",
doi = "10.1093/icvts/ivw171",
language = "English",
volume = "23",
pages = "637--646",
journal = "Interactive Cardiovascular and Thoracic Surgery",
issn = "1569-9293",
publisher = "European Association for Cardio-Thoracic Surgery",
number = "4",

}

TY - JOUR

T1 - Cardiac protection with phosphocreatine

T2 - A meta-analysis

AU - Landoni, Giovanni

AU - Zangrillo, Alberto

AU - Lomivorotov, Vladimir V.

AU - Likhvantsev, Valery

AU - Ma, Jun

AU - De Simone, Francesco

AU - Fominskiy, Evgeny

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Phosphocreatine (PCr) plays an important role in the energy metabolism of the heart and a decrease in its intracellular concentration results in alteration of myocardium energetics and work. We conducted a meta-analysis of all randomized and matched trials that compared PCr with placebo or standard treatment in patients with coronary artery disease or chronic heart failure or in those undergoing cardiac surgery. We systematically searched PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials and Google Scholar up to 1 November 2015, for pertinent trials. The primary outcome was all-cause mortality. Secondary outcomes included inotrope use, ejection fraction (EF), peak creatinine kinase-myocardial band (CK-MB) release and the incidence of major arrhythmias, as well as spontaneous recovery of the heart performance in the subgroup of patients undergoing cardiac surgery with cardiopulmonary bypass. We pooled odds ratio (OR) and mean difference (MD) using fixed- and random effects models. We identified 41 controlled trials, of them 32 were randomized. Patients receiving PCr had lower all-cause mortality when compared with the control group [61/1731 (3.5%) vs 177/1667 (10.6%); OR: 0.71, 95% CI: 0.51-0.99; P = 0.04; I2 = 0%; with 3400 patients and 22 trials included]. Phosphocreatine administration was associated with higher LVEF (MD: 3.82, 95% CI: 1.18-6.46; P = 0.005; I2 = 98%), lower peak CK-MB release (MD: -6.08, 95% CI: -8.01, -4.15; P < 0.001; I2 = 97%), lower rate of major arrhythmias (OR: 0.42; 95% CI: 0.27-0.66; P < 0.001; I2 = 0%), lower incidence of inotropic support (OR: 0.39, 95% CI: 0.25-0.61; P < 0.001; I2 = 56%) and a higher level of spontaneous recovery of the heart performance after cardiopulmonary bypass (OR: 3.49, 95% CI: 2.28-5.35; P < 0.001; I2 = 49%) when compared with the control group. In a mixed population of patients with coronary artery disease, chronic heart failure or in those undergoing cardiac surgery, PCr may reduce all-cause short-term mortality. In addition, PCr administration was associated with improved cardiac outcomes. Owing to the pharmacological plausibility of this effect and to the concordance of the beneficial effects of PCr on several secondary but important outcomes and survival, there is urgent need for a large multicentre randomized trial to confirm these findings.

AB - Phosphocreatine (PCr) plays an important role in the energy metabolism of the heart and a decrease in its intracellular concentration results in alteration of myocardium energetics and work. We conducted a meta-analysis of all randomized and matched trials that compared PCr with placebo or standard treatment in patients with coronary artery disease or chronic heart failure or in those undergoing cardiac surgery. We systematically searched PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials and Google Scholar up to 1 November 2015, for pertinent trials. The primary outcome was all-cause mortality. Secondary outcomes included inotrope use, ejection fraction (EF), peak creatinine kinase-myocardial band (CK-MB) release and the incidence of major arrhythmias, as well as spontaneous recovery of the heart performance in the subgroup of patients undergoing cardiac surgery with cardiopulmonary bypass. We pooled odds ratio (OR) and mean difference (MD) using fixed- and random effects models. We identified 41 controlled trials, of them 32 were randomized. Patients receiving PCr had lower all-cause mortality when compared with the control group [61/1731 (3.5%) vs 177/1667 (10.6%); OR: 0.71, 95% CI: 0.51-0.99; P = 0.04; I2 = 0%; with 3400 patients and 22 trials included]. Phosphocreatine administration was associated with higher LVEF (MD: 3.82, 95% CI: 1.18-6.46; P = 0.005; I2 = 98%), lower peak CK-MB release (MD: -6.08, 95% CI: -8.01, -4.15; P < 0.001; I2 = 97%), lower rate of major arrhythmias (OR: 0.42; 95% CI: 0.27-0.66; P < 0.001; I2 = 0%), lower incidence of inotropic support (OR: 0.39, 95% CI: 0.25-0.61; P < 0.001; I2 = 56%) and a higher level of spontaneous recovery of the heart performance after cardiopulmonary bypass (OR: 3.49, 95% CI: 2.28-5.35; P < 0.001; I2 = 49%) when compared with the control group. In a mixed population of patients with coronary artery disease, chronic heart failure or in those undergoing cardiac surgery, PCr may reduce all-cause short-term mortality. In addition, PCr administration was associated with improved cardiac outcomes. Owing to the pharmacological plausibility of this effect and to the concordance of the beneficial effects of PCr on several secondary but important outcomes and survival, there is urgent need for a large multicentre randomized trial to confirm these findings.

KW - Cardiac surgery

KW - Heart failure

KW - Mortality

KW - Myocardial infarction

KW - Phosphocreatine

UR - http://www.scopus.com/inward/record.url?scp=84991101876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991101876&partnerID=8YFLogxK

U2 - 10.1093/icvts/ivw171

DO - 10.1093/icvts/ivw171

M3 - Article

AN - SCOPUS:84991101876

VL - 23

SP - 637

EP - 646

JO - Interactive Cardiovascular and Thoracic Surgery

JF - Interactive Cardiovascular and Thoracic Surgery

SN - 1569-9293

IS - 4

ER -